August 2026 Dividend Stock Screen: Identifying Strong, Undervalued US Equities
Finance

August 2026 Dividend Stock Screen: Identifying Strong, Undervalued US Equities

authorBy Lisa Jing
DateAug 02, 2026
Read time2 min

In this analysis, a comprehensive dividend stock screen for August 2026 has identified 25 U.S. equities that demonstrate both strong underlying financial health and appealing valuations. These companies offer dividend yields above 2.5%, making them attractive prospects for income-focused investors. On average, the top 25 stocks identified in this screen boast a dividend yield of 3.15%, a compelling 16% undervaluation relative to their intrinsic worth, and an impressive projected compound annual growth rate (CAGR) of 14.17%.

Further in-depth evaluation using specialized Custom Dividend Yield Theory and Free Cash Flow models reinforces the findings, indicating substantial discounts for several well-known corporations. Noteworthy examples include Zoetis, a global animal health company; Accenture, a leading professional services firm; and Amdocs, a provider of software and services to communications and media companies. These insights enable investors to construct portfolios tailored to specific objectives, whether prioritizing high yield, rapid dividend growth, or maximum undervaluation opportunities.

The strategic identification of these undervalued, dividend-paying stocks serves as a testament to diligent research and a forward-looking approach to investment. By combining fundamental strength with attractive yields and growth potential, investors can seek to build resilient portfolios designed for long-term prosperity and financial security, navigating market fluctuations with confidence and a focus on sustainable returns.

More Articles
Finance
Applied Materials Achieves Record Performance and Positive Outlook
Applied Materials reported record Q2 FY2026 revenue of $7.91 billion, marking an 11% year-over-year increase, alongside a 20% rise in non-GAAP EPS to $2.86. The company's management has increased its equipment growth forecast for calendar year 2026 to over 30%, driven by enhanced order visibility and strong performance in the DRAM and AGS sectors. Despite a significant stock correction, the company's fundamentals remain robust, suggesting an attractive entry point for investors.
By Michele FerreroAug 01, 2026
Finance
The $500,000 Net Worth by 40: Reality vs. Social Media Hype
This article examines the reality of achieving a $500,000 net worth by age 40, contrasting it with social media portrayals. It reveals that only a small percentage of young Americans reach this financial milestone, with the median net worth for those under 40 being significantly lower. The article delves into how this net worth is typically distributed, highlighting the impact of home equity, retirement accounts, and stock investments. It also explores the major financial challenges faced by individuals in their 20s and 30s and outlines key factors that contribute to accumulating substantial wealth early in life.
By David RubensteinAug 01, 2026
Finance
Schwab International Equity ETF: A Comprehensive Investment Analysis
The Schwab International Equity ETF (SCHF) tracks the FTSE Developed ex US Index, providing broad international developed market exposure. Its significant allocation to Japanese equities is supported by robust wage growth, moderate inflation, and strong corporate buybacks, though valuations are above historical averages. I am cautious on US tech due to aggressive capital expenditure and market euphoria, preferring to allocate new capital to SCHF's international mix for balanced global exposure. SCHF is positioned as a core holding for investors seeking international diversification outside the U.S. equity market.
By Mariana MazzucatoAug 01, 2026
Finance
Collegium Pharmaceutical: A Shifting Horizon Beyond Pain Management
Collegium Pharmaceutical (COLL) is strategically moving from pain management to a CNS-focused platform, leveraging existing cash flows to expand its ADHD product line. The acquisition of AZSTARYS is a pivotal step, projected to generate substantial revenue and synergies, enhancing COLL's financial outlook. Despite strong growth prospects and immediate EBITDA accretion, the market appears to undervalue COLL's transformative shift, presenting a potential opportunity for investors.
By Fareed ZakariaAug 01, 2026
Finance
Crocs: Assessing the Shifting Sands of Growth and Valuation
Crocs, Inc. (CROX) stock reached its $140 target, driven by deleveraging and buybacks. However, growth has significantly slowed. Despite exceeding Q2 expectations, the stock dropped 7% due to management's flat Q3 revenue guidance and compressing margins, revealing a lack of immediate growth catalysts. Currently, CROX trades at a low 9.75x forward earnings, but with minimal future growth, declining free cash flow, and weakness in the HEYDUDE brand, it remains inexpensive without a clear catalyst, making it a 'Hold' rather than a 'Buy.'
By Nouriel RoubiniAug 01, 2026